|
1
|
Barata PC and Rini BI: Treatment of renal
cell carcinoma: Current status and future directions. CA Cancer J
Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Meerleer G, Khoo V, Escudier B, Joniau
S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N,
et al: Radiotherapy for renal-cell carcinoma. Lancet Oncol.
15:e170–e177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oosterwijk E, Rathmell WK, Junker K,
Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H
and Belldegrun A: Basic research in kidney cancer. Eur Urol.
60:622–633. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ficarra V, Guillè F, Schips L, de la
Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara G,
Zigeuner R, Bratti E, et al: Proposal for revision of the TNM
classification system for renal cell carcinoma. Cancer.
104:2116–2123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan M, Zhang L, Wu Y, Gao L, Yang W, Li J,
Chen Y and Jin X: Increased expression of kindlin-2 is correlated
with hematogenous metastasis and poor prognosis in patients with
clear cell renal cell carcinoma. FEBS Open Bio. 6:660–665. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soultati A, Stares M, Swanton C, Larkin J
and Turajlic S: How should clinicians address intratumour
heterogeneity in clear cell renal cell carcinoma? Curr Opin Urol.
25:358–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalvakolanu DV: The GRIMs: A new interface
between cell death regulation and interferon/retinoid induced
growth suppression. Cytokine Growth Factor Rev. 15:169–194. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chidambaram NV, Angell JE, Ling W, Hofmann
ER and Kalvakolanu DV: Chromosomal localization of human GRIM-19, a
novel IFN-beta and retinoic acid-activated regulator of cell death.
J Interferon Cytokine Res. 20:661–665. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu H and Cao X: GRIM-19 is essential for
maintenance of mitochondrial membrane potential. Mol Biol Cell.
19:1893–1902. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fearnley IM, Carroll J, Shannon RJ,
Runswick MJ, Walker JE and Hirst J: GRIM-19, a cell death
regulatory gene product, is a subunit of bovine mitochondrial
NADH:ubiquinone oxidoreductase (complex I). J Biol Chem.
276:38345–38348. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan XY, Jiang ZF, Cai L and Liu RY:
Expression and clinical significance of GRIM-19 in lung cancer. Med
Oncol. 29:3183–3189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Hao H, Zhao S, Liu Q, Yuan Q, Ni
S, Wang F, Liu S, Wang L and Hao A: Downregulation of GRIM-19
promotes growth and migration of human glioma cells. Cancer Sci.
102:1991–1999. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou Y, Li M, Wei Y, Feng D, Peng C, Weng
H, Ma Y, Bao L, Nallar S, Kalakonda S, et al: Down-regulation of
GRIM-19 expression is associated with hyperactivation of
STAT3-induced gene expression and tumor growth in human cervical
cancers. J Interferon Cytokine Res. 29:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Angell JE, Lindner DJ, Shapiro PS, Hofmann
ER and Kalvakolanu DV: Identification of GRIM-19, a novel cell
death-regulatory gene induced by the interferon-beta and retinoic
acid combination, using a genetic approach. J Biol Chem.
275:33416–33426. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F, Ren W, Zhao Y, Fu Z, Ji Y, Zhu Y and
Qin C: Downregulation of GRIM-19 is associated with hyperactivation
of p-STAT3 in hepatocellular carcinoma. Med Oncol. 29:3046–3054.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong D, Zhao L, Du Y, He P, Zou Y, Yang L,
Sun L, Wang H, Xu D, Meng X, et al: Overexpression of GRIM-19, a
mitochondrial respiratory chain complex I protein, suppresses
hepatocellular carcinoma growth. Int J Clin Exp Pathol.
7:7497–7507. 2014.PubMed/NCBI
|
|
17
|
Bu X, Zhao C, Wang W and Zhang N: GRIM-19
inhibits the STAT3 signaling pathway and sensitizes gastric cancer
cells to radiation. Gene. 512:198–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bezhanova SD: Tumors of the kidney. The
new 2016 WHO classification of tumors of the genitourinary system.
Arkh Patol. 79:48–52. 2017.(In Russian). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu L and Yang W: Criteria for judging the
results of immunohistochemistry. Chin Oncol. 6:31996.
|
|
21
|
Alchanati I, Nallar SC, Sun P, Gao L, Hu
J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, et al: A
proteomic analysis reveals the loss of expression of the cell death
regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene.
25:7138–7147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui L, Meng Q, Wen J, Yan Z, Gao Z, Tian
Y, Xu P, Lian P and Yu H: The effect of a gene associated with
retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced
gene expression in renal carcinoma. J Biochem. 164:285–294. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hao M, Shu Z, Sun H, Sun R, Wang Y, Liu T,
Ji D and Cong X: GRIM-19 expression is a potent prognostic marker
in colorectal cancer. Hum Pathol. 46:1815–1820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shao YP, Cheng XD and Wan XY: Expression
and clinical significance of GRIM-19 in epithelial ovarian
carcinoma. Zhonghua Fu Chan Ke Za Zhi. 47:751–755. 2012.(In
Chinese). PubMed/NCBI
|
|
25
|
Zhou T, Chao L, Rong G, Wang C, Ma R and
Wang X: Down-regulation of GRIM-19 is associated with STAT3
overexpression in breast carcinomas. Hum Pathol. 44:1773–1779.
2013. View Article : Google Scholar : PubMed/NCBI
|
